Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Last updated:
2026-08-15
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

MASTER PROTOCOL: A MASTER PROTOCOL FOR PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE WEEKLY ELORALINTIDE IN ADULT PARTICIPANTS WITH OSTEOARTHRITIS KNEE PAIN, AND OBESITY OR OVERWEIGHT (ENLIGHTEN-4)

Intervention/treatment:
ELORALINTIDE (LY3841136)
Medical condition:
OBESITY
Protocol code:
J3R-MC-YDAN
Control number:
305933
Status:
Recruiting
Approved:
February 25, 2026
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07353931
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role
CONTACT
Phone:
317-615-4559
Name
Physicians interested in becoming principal investigators please contact
Role
CONTACT
Sponsor
ELI LILLY CANADA INC

Locations

Apex Trials
Guelph, N1G 0B4
Recruiting
Role
CONTACT
Phone:
519-341-3367
Name
Ken Woo
Role
PRINCIPAL_INVESTIGATOR
Diex Recherche Inc. Division Quebec
Québec, G1V 4T3
Recruiting
Role
CONTACT
Phone:
5144773439
Name
Caroline Rheaume
Role
PRINCIPAL_INVESTIGATOR
Diex Recherche Inc. Division Victoriaville
Victoriaville, G6P 3Z8
Recruiting
Role
CONTACT
Phone:
819-260-1172
Name
Eve Betit
Role
PRINCIPAL_INVESTIGATOR
Dr. Anil K. Gupta Medicine Professional Corporation
Toronto, M9V 4B4
Recruiting
Role
CONTACT
Phone:
6473442020
Name
Anil Gupta
Role
PRINCIPAL_INVESTIGATOR
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc.
Québec, G1V 4K5
Not yet recruiting
Role
CONTACT
Phone:
418 650-2661
Name
Louis Bessette
Role
PRINCIPAL_INVESTIGATOR
Maple Leaf Research
Toronto, M5G 1K2
Recruiting
Name
Mona Loutfy
Role
PRINCIPAL_INVESTIGATOR
Stouffville Medical Research Institute Inc.
Stouffville, L4A 1H2
Recruiting
Role
CONTACT
Phone:
(905) 640-3100
Name
Nima Mirtorabi
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?